SCHEMBL31108301

SCHEMBL31108301

COC(OC)c1ccc(C(=O)Nc2cccc(-c3cccc(NC(=O)c4ccc(CN5C[C@H](O)C[C@H]5C(=O)O)cn4)c3Cl)c2C)nc1

nearest known ligand 0.62

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
▸ CD274 Q9NZQ7 20/20 0.62
▸ PDCD1 Q15116 19/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31108354 0.95 PDCD1 (0.55) CD274PDCD1
SCHEMBL20293695 0.88 CD274 (0.62) CD274PDCD1
SCHEMBL31108296 0.88 CD274 (0.62) CD274PDCD1
SCHEMBL20293698 0.88 CD274 (0.62) CD274PDCD1
SCHEMBL30127838 0.88 CD274 (0.62) CD274PDCD1
SCHEMBL20304863 0.86 PDCD1 (0.60) CD274PDCD1
SCHEMBL20293694 0.86 PDCD1 (0.60) CD274PDCD1
SCHEMBL20293691 0.86 PDCD1 (0.60) CD274PDCD1
SCHEMBL31108258 0.84 CD274 (0.62) CD274PDCD1
SCHEMBL20321396 0.84 PDCD1 (0.66) CD274PDCD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4694981-A1 HETEROCYCLIC COMPOUNDS AS DUAL INHIBITORS OF PD-L1 AND ADENOSINE RECEPTORS Aurigene Oncology Limited (IN) 2026-02-18 — — EP disclosed
WO-2024214088-A1 HETEROCYCLIC COMPOUNDS AS DUAL INHIBITORS OF PD-L1 AND ADENOSINE RECEPTORS AURIGENE ONCOLOGY LIMITED (IN) 2024-10-17 — — WO disclosed
Send feedback